NPY and cardiac diseases

Current Topics in Medicinal Chemistry

Volumn 7, Issue 17, 2007, Pages 1692-1703

  McDermott, B J ^a   Bell, D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cardiomyocyte; Heart failure; Hypertension; Ischemia; Left ventricular hypertrophy; Myocardial infarction; Neuropeptide Y; Y receptors

Indexed keywords

1 NAPHTHALENESULFONIC ACID [4 [(4 AMINO 2 QUINAZOLINYLAMINO)METHYL]CYCLOHEXYLMETHYL]AMIDE; AR H 040922; BIIE 2006; LOSARTAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR ANTAGONIST; NEUROPEPTIDE Y3 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; PROTEIN KINASE C; QUINAPRIL; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COMPETITIVE INHIBITION; ENDOTHELIUM CELL; GENE DELETION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART RATE VARIABILITY; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASOCONSTRICTION;

EID: 36248937836     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607782340939     Document Type: Review

References (161)

1. Ritter, O.; Neyses, L. The molecular basis of myocardial hypertrophy and heart failure. Trends Mol. Med. 2003, 9, 313-321.
2. Swynghedauw, B. Phenotypic plasticity of adult myocardium: molecular mechanisms. J. Exp. Biol. 2006, 209, 2320-2327.
3. Lorell, B.H.; Carabello, B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000, 102, 470-479.
4. Opie, L.H.; Commerford, P.J.; Gersh, B.J.; Pfeffer, M.A. Controversies in ventricular remodelling. Lancet 2006, 367, 356-367.
5. Gradman, A.H.; Alfayoumi, F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog. Cardiovasc. Dis. 2006, 48, 326-341.
6. Dendorfer, A.; Dominiak, P.; Schunkert, H. ACE inhibitors and angiotensin II receptor antagonists. Handb. Exp. Pharmacol. 2005, 170, 407-442.
7. Lindholm, L.H.; Carlberg, B.; Samuelsson, O. Beta blockers in primary hypertension: Do age and type of beta-blocker matter? J. Hypertens. 2006, 24, 2143-2145.
8. Sato, A.; Saruta, T.; Funder, J.W. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens. Res. 2006, 29, 211-216.
9. Meredith, P.A.; Ostergren, J. From hypertension to heart failure - are there better primary prevention strategies? J. Renin Angiotensin Aldosterone Syst. 2006, 7, 64-73.
10. Tatemoto, K.; Carlquist, M.; Mutt, V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 1982, 296, 659-660.
11. Pedrazzini, T.; Pralong, F.; Grouzmann, E. Neuropeptide Y: the universal soldier. Cell Mol. Life Sci. 2003, 60, 350-377.
12. Walker, P.; Grouzmann, E.; Burnier, M.; Waeber, B. The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol. Sci. 1991, 12, 111-115.
13. Haass, M.; Cheng, B.; Richardt, G.; Lang, R.E.; Schomig, A. Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn Schmiedebergs Arch. Pharmacol. 1989, 339, 71-78.
14. Potter, E.K.; Mitchell, L.; McCloskey, M.J.; Tseng, A.; Goodman, A.E.; Shine, J.; McCloskey, D.I. Pre- and postjunctional actions of neuropeptide Y and related peptides. Regul. Pept. 1989, 25, 167-177.
15. Gu, J.; Polak, J.M.; Allen, J.M.; Huang, W.M.; Sheppard, M.N.; Tatemoto, K.; Bloom, S.R. High concentrations of a novel peptide, neuropeptide Y, in the innervation of mouse and rat heart. J. Histochem. Cytochem. 1984, 32, 467-472.
16. McDermott, B.J; Millar, B.C.; Piper, H.M. Cardiovascular effects of neuropeptide Y: receptor interactions and cellular mechanisms. Cardiovasc. Res. 1993, 27, 893-905.
17. Zukowska-Grojec, Z; Karwatowska-Prokopczuk, E.; Rose, W.; Rone, J.; Movafagh, S.; Ji, H.; Yeh, Y.; Chen, W.T.; Kleinman, H.K.; Grouzmann, E.; Grant, D.S. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 1998, 83, 187-195.
18. Zukowska-Grojec, Z.; Karwatowska-Prokopczuk, E.; Fisher, T.A.; Ji, H. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul. Pept. 1998, 75-76, 231-238.
19. Pons, J.; Kitlinska, J.; Ji, H.; Lee, E.W.; Zukowska, Z. Mitogenic actions of neuropeptide Y in vascular smooth Muscle cells: synergetic interactions with the beta-adrenergic system. Can. J. Physiol. Pharmacol. 2003, 81, 177-185.
20. Millar, B.C.; Schluter, K.D.; Zhou, X.J.; McDermott; B.J.; Piper, H.M. Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes. Am. J. Physiol. 1994, 266, C1271-7.
21. Michel, M.C.; Beck-Sickinger, A. Cox.; H.; Doods, H.N.; Herzog, H.; Larhammar, D.; Quirion, R.; Schwartz, T.; Westfall, T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 1998, 50, 143-150.
22. Silva, A.P.; Cavadas, C.; Grouzmann, E. Neuropeptide Y and its receptors as potential therapeutic drug targets. Clin. Chim. Acta. 2002, 326, 3-25.
23. Rudolf, K.; Eberlein, W.; Engel, W.; Wieland, H.A.; Willim, K.D.; Entzeroth, M.; Wienen, W.; Beck-Sickinger, A.G.; Doods, H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 1994, 271, R11-3.
24. Doods, H.; Gaida, W.; Wieland, H.A:; Dollinger, H.; Schnorrenberg, G.; Esser, F.; Engel, W.; Eberlein, W.; Rudolf, K. BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist. Eur. J. Pharmacol. 1999, 384, R3-5.
25. Malmstrom, R.E. Pharmacology of neuropeptide Y receptor antagonists. Focus on cardiovascular functions. Eur. J. Pharmacol. 2002, 447, 11-30.
26. Berglund, M.M.; Schober, D.A.; Esterman, M.A.; Gehlert, D.R. Neuropeptide Y Y4 receptor homodimers dissociate upon agonist stimulation. J. Pharmacol. Exp. Ther. 2003, 307, 1120-1126.
27. Chronwall, B.M.; Zukowska, Z. Neuropeptide Y, ubiquitous and elusive. Peptides 2004, 25, 359-363.
28. Westfall, T.C. Neuropeptide Y and sympathetic control of vascular tone in hypertension. EXS 2006 95, 89-103.
29. Edvinsson, L.; Ekman, R.; Thulin, T. Increased plasma levels of neuropeptide Y-like immunoreactivity and catecholamines in severe hypertension remain after treatment to normotension in man. Regul. Pept. 1991, 32, 279-287.
30. Hulting, J.; Sollevi, A.; Ullman, B.; Franco-Cereceda, A.; Lundberg, J.M. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc. Res. 1990, 24, 102-108.
31. Madsen, B.K.; Husum, D.; Videbaek, R.; Stokholm, K.H.; Saelsen, L.; Christensen, N.J. Plasma immunoreactive neuropeptide Y in congestive heart failure at rest and during exercise. Scand. J. Clin. Lab. Invest. 1993, 53, 569-576.
32. Ullman, B.; Jensen-Urstad, M.; Hulting, J.; Lundberg, J.M. Neuropeptide Y, noradrenaline and invasive haemodynamic data in mild to moderate chronic congestive heart failure. Clin. Physiol. 1993, 13, 409-418.
33. Lin, J.J.; Shi, S.G.; Han, Q.D. Evaluation of plasma neuropeptide Y levels in patients with congestive heart failure. Zhonghua Nei Ke Za Zhi 1994, 33, 687-689.
34. Onuoha, G.N.; Nugent, A.M.; Hunter, S.J.; Alpar, E.K.; McEneaney, D.J.; Campbell, N.P.; Shaw, C. Buchanan,; K.D.; Nicholls, D.P. Neuropeptide variability in man. Eur. J. Clin. Invest. 2000, 30, 570-577.
35. Ullman, B.; Hulting, J.; Lundberg, J.M. Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur. Heart J. 1994, 15, 454-461.
36. Ullman, B.; Franco-Cereceda, A.; Hulting, J.; Lundberg, J.M.; Sollevi, A. Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J. Intern. Med. 1990, 228, 583-589.
37. Omland, T.; Opstad, K.; Dickstein, K. Plasma neuropeptide Y levels in the acute and early convalescent phase after myocardial infarction. Am. Heart J. 1994, 127, 774-779.
38. Karvonen, M.K.; Pesonen, U.; Koulu, M.; Niskanen, L.; Laakso, M.; Rissanen, A.; Dekker, J.M.; Hart, L.M.; Valve, R.; Uusitupa, M.I. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat. Med. 1998, 4, 1434-1437.
39. Bray, M.S.; Boerwinkle, E.; Hanis, C.L. Sequence variation within the neuropeptide Y gene and obesity in Mexican Americans. Obes. Res. 2000, 8, 219-226.
40. Herzog, H.; Baumgartner, M.; Vivero, C.; Selbie, L.A.; Auer, B.; Shine, J. Genomic organization, localization, and allelie differences in the gene for the human neuropeptide Y Y1 receptor. J. Biol. Chem. 1993, 268, 6703-6707.
41. Rosenkranz, K.; Hinney, A.; Ziegler, A.; von Prittwitz, S.; Barth, N.; Roth, H.; Mayer, H.; Siegfried, W.; Lehmkuhl, G.; Poustka, F.; Schmidt, M.; Schafer, H.; Remschmidt, H.; Hebebrand, J. Screening for mutations in the neuropeptide Y Y5 receptor gene in cohorts belonging to different weight extremes. Int. J. Obes. Relat. Metab. Disord. 1998, 22, 157-163.
42. Jenkinson, C.P.; Cray, K.; Walder, X.; Herzog, H.; Hanson; Ravussin, E. Novel polymorphisms in the neuropeptide-Y Y5 receptor, associated with obesity in Pima Indians. Int. J. Obes. Relat. Metab. Disord. 2000, 24, 580-584.
43. Blumenthal, J.B.; Andersen, R.E.; Mitchell, B.D.; Seibert, M.J.; Yang, H.; Herzog, H.; Beamer, B.A.; Franckowiak, S.C.; Walston, J.D. Novel neuropeptide Y1 and Y5 receptor gene variants: associations with serum triglyceride and high-density lipoprotein cholesterol levels. Clin. Genet. 2002, 62, 196-202.
44. Dumont, Y.; Quirion, R. An overview of neuropeptide Y: pharmacology to molecular biology and receptor localization. EXS 2006, 95, 7-33.
45. Koglin, N.; Beck-Sickinger, A.G. Novel modified and radiolabelled neuropeptide Y analogues to study Y-receptor subtypes. Neuropeptides 2004, 38, 153-161.
46. Lin, S.; Boey, D.; Herzog, H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 2004, 38, 189-200.
47. Pedrazzini, T. Importance of NPY Y1 receptor-mediated pathways: assessment using NPY Y1 receptor knockouts. Neuropeptides, 2004, 38, 267-275.
48. Zhuo, J.L. Neuropeptide Y T1128C polymorphism: an independent predictor of hypertensive and cardiovascular diseases? J. Hypertens. 2004, 22, 1251-1253.
49. Pesonen, U. Human NPY gene variants in cardiovascular and metabolic diseases. EXS 2006, 95, 247-267.
50. Balasubramaniam, A. Clinical potentials of neuropeptide Y family of hormones. Am. J. Surg. 2002, 183, 430-434.
51. Zukowska, Z.; Grant, D.S.; Lee, E.W. Neuropeptide Y: a novel mechanism for ischemic angiogenesis. Trends Cardiovasc. Med. 2003, 13, 86-92.
52. Jacques, D.; Sader, S.; Perreault, C.; Abdel-Samad, D. NPY and NPY receptors: presence, distribution and roles in the regulation of the endocardial endothelium and cardiac function. EXS 2006, 95, 77-87.
53. Jacques, D.; Sader, S.; Perreault, C.; Abdel-Samad, D.; Jules, F.; Provost, C. NPY, ET-1, and Ang II nuclear receptors in human endocardial endothelial cells. Can. J. Physiol. Pharmacol. 2006, 84, 299-307.
54. Jacques, D.; Sader, S.; Perreault, C.; Abdel-Samad, D.; Provost, C. Roles of nuclear NPY and NPY receptors in the regulation of the endocardial endothelium and heart function. Can. J. Physiol. Pharmacol. 2006, 84, 695-705.
55. Feuerstein, G.Z.; Lee, E.W. Neuropeptide Y and the heart: implication for myocardial infarction and heart failure. EXS 2006, 95, 113-122.
56. Han, C.; Wang, X.A.; Fiscus, R.R.; Gu, J.; McDonald, J.K. Changes in cardiac neuropeptide Y after experimental myocardial infarction in rat. Neurosci. Lett. 1989, 104, 141-146.
57. Onuoha, G.N.; Nicholls, D.P.; Alpar, E.K.; Ritchie, A.; Shaw, C.; Buchanan, K. Regulatory peptides in the heart and major vessels of man and mammals. Neuropeptides 1999 33, 165-172.
58. Richardson, R.J.; Grkovic, I.; Anderson, C.R. Immumohistochemical analysis of intracardiac ganglia of the rat heart. Cell Tissue Res. 2003, 314, 337-350.
59. Franco-Cereceda, A.; Lundberg, JM.; Dahlof, C. Neuropeptide Y and sympathetic control of heart contractility and coronary vascular tone. Acta Physiol. Scand. 1985, 124, 361-369.
60. Marron, K.; Wharton, J.; Sheppard, M.N.; Gulbenkian, S.; Royston, D.; Yacoub, M.H.; Anderson, R.H.; Polak, J.M. Human endocardial innervation and its relationship to the endothelium: an immunohistochemical, histochemical, and quantitative study. Cardiovasc. Res. 1994, 28, 1490-1499.
61. Richardson, R.J.; Grkovic, I.; Allen, A.M.; Anderson, C.R. Separate neurochemical classes of sympathetic postganglionic neurons project to the left ventricle of the rat heart. Cell Tissue Res. 2006, 324, 9-16.
62. Gray, A.L.; Johnson, T.A.; Lauenstein, J.M.; Newton, S.S.; Ardell, J.L.; Massari, V.J. Parasympathetic control of the heart. III. Neuropeptide Y-immunoreactive nerve terminals synapse on three populations of negative chronotropic vagal preganglionic neurons. J. Appl. Physiol. 2004, 96, 2279-2287.
63. Shoba, T.; Tay, S.S. Nitrergic and peptidergic innervation in the developing rat heart. Anat. Embryol. (Berl) 2000, 201, 491-500.
64. Hassall, C.J.; Burnstock, G. Neuropeptide Y-like immunoreactivity in cultured intrinsic neurones of the heart. Neurosci. Lett. 1984, 52, 111-115.
65. Gulbenkian, S.; Edvinsson, L.; Saetrum Opgaard, O.; Wharton, J.; Polak, I.M.; David-Ferreira, J.F. Peptide-containing nerve fibres-in guinea-pig coronary arteries: immunohistochemistry, ultrastructure and vasomotility. J. Auton. Nerv. Syst. 1990, 31, 153-167.
66. Jacques, D.; Sader, S.; Perreault, C.; Fournier, A.; Pelletier, G.; Beck-Sickinger, A.G.; Descorbeth, M. Presence of neuropeptide Y and the Y1 receptor in the plasma membrane and nuclear envelope of human endocardial endothelial cells: modulation of intracellular-calcium. Can. J. Physiol. Pharmacol. 2003, 81, 288-300.
67. Bell, D.; Allen, A.R.; Kelso, E.J.; Balasubramaniam, A.; McDermott, B.J. Induction of hypertrophic responsiveness of cardiomyocytes to neuropeptide Y in response to pressure overload. J. Pharmacol. Exp. Ther. 2002, 303, 581-591.
68. Inoue, H.; Zipes, D.P. Time course of denervation of efferent sympathetic and vagal nerves after occlusion of the coronary artery in the canine heart. Circ. Res. 1988, 62, 1111-1120.
69. Cheng, B.; He, Y.; Xiang, J.; Guo, L.; Han, Q. An animal and clinical study on the change of neuropeptide Y release evoked by electrical stimulation, and myocardial ischemia. Chin. Med. J. (Engl) 1999, 112, 410-413.
70. Li, W.; Knowlton, D.; Van Winkle, D.M.; Habecker, B.A. Infarction alters both the distribution and noradrenergic properties of cardiac sympathetic neurons. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H2229-36.
71. Zigmond, R.E.; Sun, Y. Regulation of neuropeptide expression in sympathetic neurons. Paracrine and retrograde influences. Ann. N. Y. Acad. Sci. 1997, 814, 181-197.
72. Habecker, B.A.; Gritman, K.R.; Willison, B.D.; Van Winkle, D.M. Myocardial infarction stimulates galanin expression in cardiac sympathetic neurons. Neuropeptides 2005, 39, 89-95.
73. Love, S.; Nyquist-Battie, C.; DiMaggio, D.A.; Farah Jr, J.M.; Chronwall, B.M. Diminished neuropeptide Y and dopamine beta-hydroxylase immunoreactivity in a guinea pig model of left ventricular hypertrophy. Cardiovasc. Res. 1993, 27, 494-499.
74. Zolk, O.; Flesch, M.; Schnabel, P.; Teisman, A.C.; Pinto, Y.M.; van Gilst, W.H.; Paul, M.; Bohm, M. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and. beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats. Br. J. Pharmacol. 1998, 123, 405-412.
75. Nyquist-Battie, C.; Cochran, P.; Chronwall, B.M. Differential effects of high salt intake on neuropeptide Y and adrenergic markers in hearts of Dah1 rats. Peptides 1998, 19, 1377-1383.
76. Kuncova, J.; Sviglerova, J.; Tonar, Z.; Slavikova, J. Heterogenous changes in neuropeptide Y, norepinephrine and epinephrine concentrations in the hearts of diabetic rats. Auton. Neurosci. 2005, 121, 7-15.
77. Zhang, X.M.; Shen, F.; Xv, Z.Y.; Yan, Z.Y.; Han, S. Expression changes of thrombospondin-1 and neuropeptide Y in myocardium of STZ-induced rats. Int. J Cardiol. 2005, 105, 192-197.
78. Malmstrom, R.E.; Lundberg, J.N.; Weitzberg, E. Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 2002, 365, 106-111.
79. Clarke, J.G.; Davies, G.J.; Kerwin, R.; Hackett, D.; Larkin, S.; Dawbam, D.; Lee, Y.; Bloom, S.R.; Yacoub, M.; Maseri, A. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet 1987, 1, 1057-1059.
80. Svendsen,, J.H.; Sheikh, S.P.; Jorgensen, J.; Mikkelsen, J.D.; Paaske, W.P.; Sejrsen, P.; Haunso, S. Effects of neuropeptide Y on regulation of blood flow rate in canine myocardium. Am. J. Physiol. 1990, 259, H1709-17.
81. Rudehill, A.; Sollevi, A.; Franco-Cereceda, A.; Lundberg, J.M. Neuropeptide Y (NPY) and the pig heart: release and coronary vasoconstrictor effects. Peptides 1986, 7, 821-826.
82. Aizawa, Y.; Satoh, M.; Aizawa, M.; Funazaki, T.; Niwano, S.; Miyajima, & Shibata, A. Potency,and receptors involved in coronary vasoconstriction caused by neuropeptide Y(NPY). Jpn. Heart J. 1987, 28, 891-898.
83. Edvinsson, L.; Ekblad, E.; Hakanson, R.; Wahlestedt, C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br. J. Pharmacol. 1984, 83, 519-525.
84. Hieble, J.P.; Daesler Jr, J.G.; Daly, R.N. Effects of neuropeptide Y on the response of isolated blood vessels to norepinephrine and sympathetic field stimulation. J. Pharmacol. Exp. Ther. 1989, 250, 523-528.
85. Lundberg, J.M.; Hua, X.Y.; Franco-Ccreceda, A. Effects of neuropeptide Y (NPY) on mechanical activity and neurotransmission in the heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiol. Scand. 1984, 121, 325-332.
86. Haass, M.; Hock, M.; Richardt, G.; Schomig, A. Neuropeptide Y differentiates between, exocytotic and nonexocytotic noradrenaline release in guinea-pig heart. Naunyn Schmiedebergs Arch. Pharmacol. 1989, 340, 509-515.
87. Serone, A.P.; Wright, C.E.; Angus, J.A. Heterogeneity of prejunctional NPY receptor-mediated inhibition of cardiac neurotransmission. Br. J. Pharmacol. 1999, 127, 99-108.
88. Serone, A.P.; Angus, J.A. Neuropeptide Y is a prejunctional inhibitor of vagal but not sympathetic inotropic responses in guinea-pig isolated left atria. Br. J. Pharmacol. 1999, 127, 383-390.
89. Dahlof, C.; Dahlof, P.; Lundberg, J.M. Neuropeptide Y (NPY): enhancement of blood pressure increase upon alpha-adrenoceptor activation and direct pressor effects in pithed rats. Eur. J. Pharmacol. 1985, 109, 289-292.
90. Piper, H.M.; Millar, B.C.; McDermott, B.J. The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte. Naunyn Schmiedebergs Arch. Pharmacol. 1989, 340, 333-337.
91. Millar, B.C.; Weis, T.; Piper, H.M.; Weber, M.; Borchard, U.; McDermott, B.J.; Balasubramaniam, A. Positive and negative contractile effects of neuropeptide Y on ventricular cardiomyocytes. Am. J. Physiol. 1991, 261, H1727-33.
92. Heredia, M.P.; Fernandez-Velasco, M.; Benito, G.; Delgado, C. Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes. Br. J. Pharmacol. 2002, 135, 1701-1706.
93. Jacques, D.; Sader, S.; El-Bizri, N.; Chouffani, S.; Hassan, G.; Shbaklo, H. Neuropeptide Y induced increase of cytosolic and nuclear Ca2+ in heart and vascular smooth muscle cells. Can. J. Physiol. Pharmacol. 2000, 78, 162-172.
94. Heredia Mdel, P.; Delgado, C.; Pereira, L.; Perrier, R.; Richard, S.; Vassort, G.; Benitah, J.P.; Gomez, A.M. Neuropeptide Y rapidly enhances [Ca2+]i transients and Ca2+ sparks in adult rat ventricular myocytes through Y1 receptor and PLC activation. J. Mol. Cell. Cardiol. 2005, 38, 205-212.
95. Michalkiewicz, M.; Michalkiewicz, T.; Kreulen, D.L.; McDougall, S.J. Increased blood pressure responses in neuropeptide Y transgenic rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281, R417-26.
96. Rosenwinkel, E.T.; Bloomfield, D.M.; Arwady, M.A.; Goldsmith, R.L. Exercise and autonomic function in health and cardiovascular disease. Cardiol. Clin. 2001, 19, 369-387.
97. Gullestad, L.; Jorgensen, B.; Bjuro, T.; Pernow, J.; Lundberg, J.M.; Dota, C.D.; Hall, C.; Simonsen, S.; Ablad, B. Postexercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease. Circulation 2000, 102, 987-993.
98. Hilfiker-Kleiner, D.; Landmesser, U.; Drexler, H. Molecular mechanisms in heart failure focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J. Am. Coll. Cardiol. 2006, 48, A56-66.
99. Ekstrand, A.J.; Cao, R.; Bjorndahl, M.; Nystrom, S.; Jonsson-Rylander, A.C.; Hassani, H.; Hallberg, B.; Nordlander, M.; Cao, Y. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogencsis and delayed wound healing. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 6033-6038.
100. Osugi, T.; Oshima, Y.; Fujio, Y.; Funamoto, M.; Yamashita, A.; Negoro, S.; Kunisada, X.; Izumi, M.; Nakaoka, Y.; Hirota, H.; Okabe, M.; Yamauchi-Takihara, K.; Kawase, I.; Kishimoto, T. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J. Biol. Chem. 2002, 277, 6676-6681.
101. Hilfiker-Kleiner, D.; Kaminski, K.; Kaminska, A.; Fuchs, M.; Klein, G.; Podewski, E.; Grote, K.; Kiian, I.; Wollert, K.C.; Hilfiker, A.; Drexler, H. Aegulation of proangiogenic factor CCN1 in cardiac muscle: impact of ischemia, pressure overload, and neurohumoral activation. Circulation 2004, 109, 2227-2233.
102. Muraoka, O.; Xu, B.; Tsurumaki, T.; Akira, S.; Yamaguchi, T.; Higuchi, H. Leptin-induced transactivation of NPY gene promoter mediated by JAK1, JAK2 and STAT3 in the neural cell lines. Neurochem. Int. 2003, 42, 591-601.
103. Schluter, K.D.; Millar, B.C.; McDermott, B.J.; Piper, H.M. Regulation of protein synthesis and degradation in adult ventricular cardiomyocytes. Am. J. Physiol. 1995, 269, C1347-55.
104. Nicholl, S.M.; Bell, D.; Spiers, J.; McDermott, B.J. Neuropeptide Y Y(1) receptor regulates protein turnover and constitutive gene expression in hypertrophying cardiomyocytes. Eur. J. Pharmacol. 2002, 441, 23-34.
105. Goldberg, Y.; Taimor, G.; Piper, H.M.; Schluter, K.D. Intracellular signaling leads to the hypertrophic effect of neuropeptide Y. Am. J. Physiol. 1998, 275, C1207-15.
106. Pellieux, C.; Sauthier, T.; Domenighetti, A.; Marsh, D.J.; Palmiter, R.D.; Brunner, H.R.; Pedrazzini, T. Neuropeptide Y (NPY) potentiates phenylephrine-induced mitogen-activated protein kinase activation in primary cardiomyocytes via NPY Y5 receptors. Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 1595-1600.
107. Zeng, C.; Zhou, Y.; Liu, G.; Sun, W. The signal transduction pathway causing the synergistic hypertrophic effects of neuropeptide Y and norepinephrine on primary cardiomyocyte. Neuropeptides 2001, 35, 211-218.
108. Kanevskij, M.; Taimor, G.; Schafer, M.; Piper, H.M.; Schluter, K.D. Neuropeptide Y modifies the hypertrophic response of adult ventricular cardiomyocytes to norepinephrine. Cardiovasc. Res. 2002, 53, 879-887.
109. Bell, D.; Kelso, E.J.; Argent, C.C.; Lee, G.R.; Allen, A.R.; McDermott, B.J. Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive rat. Cardiovasc. Pathol. 2004, 13, 71-78.
110. Bohm, M.; Gierschik, P.; Knorr, A.; Larisch, K.; Weismann, K.; Erdmann, E. Desensitization of adenylate cyclase and increase of Gi alpha in cardiac hypertrophy due to acquired hypertension. Hypertension 1992, 20, 103-112.
111. Bohm, M.; Kirchmayr, R.; Erdmann, E. Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock. Cardiovasc. Res. 1995, 30, 611-618.
112. Kawamoto, H.; Ohyanagi, M.; Nakamura, K. Yamamoto, J.; Iwasaki, T. Increased levels of inhibitory G protein in myocardium with heart failure. Jpn. Circ. J. 1994, 58, 913-924.
113. Balasubramaniam, A.A. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides 1997, 18, 445-457.
114. Movafagh, S.; Hobson, J.P.; Spiegel, S.; Kleinman, H.K.; Zukowska, Z. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J. 2006, 20, 1924-1926.
115. Costoli, T.; Sgoifo, A.; Stilli, D.; Flugge, G.; Adriani, W.; Laviola, G.; Fuchs, E., Pedrazzini, T;. Musso, E. Behavioural, neural and cardiovascular adaptations in mice lacking the NPY Y1 receptor. Neurosci. Biobehav. Rev. 2005, 29, 113-123.
116. Allen, C.J.; Ghilardi, J.R.; Vigna, S.R.; Mannon, P.J.; Taylor, I.L.; McVey, D.C.; Maggio, J.E.; Mantyh, P.W. Neuropeptide Y/peptide YY receptor binding sites in the heart: localization and pharmacological characterization. Neuroscience 1993, 53, 889-898.
117. Wharton, J.; Gordon, L.; Byrne, J.; Herzog, H.; Selbie, L.A.; Moore, K.; Sullivan, M.H.; Elder, M.G.; Moscoso, G.; Taylor, K.M. Expression of the human neuropeptide tyrosine Y1 receptor. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 687-691.
118. Matsuda, H.; Brumovsky, P.R.; Kopp, J.; Pedrazzini, T.; Hokfelt, T. Distribution of neuropeptide Y Y1 receptors in rodent peripheral tissues. J. Comp. Neurol. 2002, 449, 390-404.
119. Uddman, R.; Moller, S.; Nilsson, T.; Nystrom S.; Ekstrand, J.; Edvinsson, L. Neuropeptide Y Y1 and neuropeptide Y Y2 receptorsin human cardiovascular tissues. Peptides 2002, 23, 927-934.
120. Pedrazzini, T.; Seydoux, J.; Kunstner, P.; Aubert, J.P.; Grouzmann, E.; Beermann, F.; Brunner, H.R. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat. Med. 1998, 4, 722-726.
121. Prieto, D.; Garcia-Sacristan, A.; Simonsen, U. Characterization of NPY receptors mediating contraction in rat intramyocardial coronary arteries. Regul. Pept. 1998, 75-76, 155-160.
122. Gullestad, L.; Bjuro, T.; Aaberge, L.; Apelland, T.; Skardal, R.; Kjekshus, E.; Nordlander, M.; Ablad, B.; Pernow, J. The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris. Eur. Heart J. 2003, 24, 1120-1127.
123. Jonsson-Rylander, A.C.; Nordlander, M.; Svindland, A.; Ilebekk, A. Distribution of neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. Peptides 2003, 24, 255-262.
124. Allen, A.R.; Kelso, E.J.; Bell, D:; Zhao, Y.; Dickson, P.; McDermott, B.J. Modulation of contractile function through neuropeptide Y receptors during development of cardiomyocyte hypertrophy. J. Pharmacol. Exp. Ther. 2006, 319, 1286-1296.
125. McDermott, B.J.; Millar, B.C.; Dolan, F.M.; Bell, D.; Balasubramaniam, A. Evidence for Y1 and Y2 subtypes of neuropeptide Y receptors linked to opposing postjunctional effects observed in rat cardiac myocytes. Eur. J. Pharmacol. 1997, 336, 257-265.
126. Xiang, H.; Brown, J.C. Inhibitory effect of neuropeptide Y and its analogues on inositol 1,4,5-trisphosphate level in rat cardiomyocytes. Receptors Channels 1993, 1, 315-321.
127. Gullestad, L.; Aass, H.; Ross, H.; Ueland, T.; Geiran, O.; Kjekshus, J.; Simonsen, S.; Fowler, M.; Kobilka, B. Neuropeptide Y receptor 1 (NPY-Y1) expression in human heart failure and heart transplantation. J. Auton. Nerv. Syst. 1998, 70, 84-91.
128. Wahlestedt, C.; Wohlfart, B.; Hakanson, R. Effects of neuropeptide Y (NPY) on isolated guinea-pig heart. Acta Physiol. Scand. 1987, 129, 459-463.
129. Naveilhan, P.; Hassani, H.; Canals, J.M.; Ekstrand, A.J.; Larefalk, A.; Chhajlani, V.; Arenas, E.; Gedda, K.; Svensson, L.; Thoren, P.; Ernfors, P. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat. Med. 1999, 3, 1188-1193.
130. Smith-White, M.A.; Herzog, H.; Potter, E.K. Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul. Pept. 2002, 103, 105-111.
131. Millar, B.C.; Piper, H.M.; McDermott, B.J. The antiadrenergic effect of neuropeptide Y on the ventricular cardiomyocyte. Naunyn Schmiedebergs Arch. Pharmacol. 1988, 338, 426-429.
132. Protas, L.; Robinson, R.B. Neuropeptide Y contributes to innervation-dependent increase in I(Ca, L) via ventricular Y2 receptors. Am. J. Physiol. 1999, 277, H940-6.
133. Qu, J.; Cohen, I.S.; Robinson, R.B. Sympathetic innervation alters activation of pacemaker current (If) in rat ventricle. J. Physiol. 2000, 526 (Pt 3), 561-569.
134. Schwertfeger, E.; Klein, T.; Vonend, O.; Oberhauser, V.; Stegbauer, J.; Rump, L.C. Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 369, 455-461.
135. Smith-White, M.A.; Wallace, D.; Potter, E.K. Sympathetic-parasympathetic interactions at the heart in the anaesthetised rat. J. Auton. Nerv. Syst. 1999, 75, 171-175.
136. Ilebekk, A.; Bjorkman, J.A.; Nordlander, M. Influence of endogenous neuropeptide Y (NPY) on the sympathetic-parasympathetic interaction in the canine heart. J. Cardiovasc. Pharmacol. 2005, 46, 474-480.
137. Lee, E.W.; Michalkiewicz, M.; Kitlinska, J.; Kalezic, I.; Switalska, H.; Yoo, P.; Sangkharat, A.; Ji, H.; Li, L.; Michalkiewicz, T.; Ljubisavljevic, M.; Johansson, H.; Grant, D.S.; Zukowska, Z. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J. Clin. Invest. 2003, 111, 1853-1862.
138. Gregor, P.; Millham, M.L.; Feng, Y.; DeCarr, L.B.; McCaleb, M.L.; Cornfield, L.J. Cloning and characterization of a novel receptor to pancreatic polypeptide, a member of the neuropeptide Y receptor family. FEBS Lett. 1996, 381, 58-62.
139. Yan, H.L; Yang, J.; Marasco, J.; Yamaguchi, K.; Brenner, S.; Collins, F.; Karbon, W. Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 4661-4665.
140. Smith-White, M.A.; Herzog, H.; Potter, E.K. Cardiac function in neuropeptide Y Y4 receptor-knockout mice. Regul. Pept. 2002, 110, 47-54.
141. Katsuya, T.; Higaki, J.; Zhao, Y.; Miki, T.; Mikami, H.; Serikawa, T.; Ogihara, T. A neuropeptide Y locus on chromosome 4 cosegregates with blood pressure in the spontaneously hypertensive rat. Biochem. Biophys. Res. Commun. 1993, 192, 261-267.
142. Ding, B. Distribution of the NPY 1128C allele frequency in different populations. J. Neural Transm. 2003, 110, 1199-1204.
143. Jia, C.; Liu, Z.; Liu, T.; Ning, Y. The T1128C polymorphism of neuropeptide Y gene in a chinese population. Arch. Med. Res. 2005, 36, 175-177.
144. Kallio, J.; Pesonen, U.; Kaipio, K.; Karvonen, M.K.; Jaakkola, U.; Heinonen, O.J.; Uusitupa, M.I.; Koulu, M. Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans. FASEB J. 2001, 15, 1242-1244.
145. Kallio, J.; Pesonen, U.; Jaakkola, U.; Karvonen, M.K.; Helenius, H.; Koulu, M. Changes in diurnal sympathoadrenal balance and pituitary hormone secretion in subjects with Leu7Pro polymorphism in the prepro-neuropeptide Y. J. Clin. Endocrinol. Metab. 2003, 88, 3278-3283.
146. Jaakkola, U.; Kuusela, T.; Jartti, T.; Pesonen, U.; Koulu, M.; Vahlberg, T.; Kallio, J. The Leu7Pro polymorphism of preproNPY is associated with decreased insulin secretion, delayed ghrelin suppression, and increased cardiovascular responsiveness to norepinephrine during oral glucose tolerance test. J. Clin. Endocrinot. Metab. 2005, 90, 3646-3652.
147. Kallio, J.; Pesonen, U.; Karvonen, M.K.; Kojima, M.; Hosoda, H.; Kangawa, K.; Koulu, M. Enhanced exercise-induced GH secretion in subjects with Pro7 substitution in the prepro-NPY. J. Clin. Endocrinol. Metab. 2001, 86, 5348-5352.
148. Halushka, M.K.; Fan, J.B.; Bentley, K.; Hsie, L.; Shen, N.; Weder, A.; Cooper, R.; Lipshutz, R.; Chakravarti, A. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat. Genet. 1999, 22, 239-247.
149. Lifton, R.P. Molecular genetics of human blood pressure variation, Science 1996, 272, 676-680.
150. Morris, B.J.; Griffiths, L.R. Scanning the genome for essential hypertension loci, Clin. Exp. Pharmacol. Physiol. Suppl. 1998, 25, S72-8.
151. Niskanen, L.; Karvonen, M.K.; Valve, R.; Koulu, M.; Pesonen, U.; Mercuri, M.; Rauramaa, R.; Toyry, J.; Laakso, M.; Uusitupa, M.I. Leucine 7 to proline 7 polymorphism in the neuropeptide Y tene is associated with enhanced carotid atherosclerosis in elderly patients with type 2 diabetes and control subjects. J Clin. Endocrinol. Metab. 2000, 85, 2266-2269.
152. Karvonen, M.K.; Valkonen, V.P.; Lakka, T.A.; Salonen, R.; Koulu, M.; Pesonen, U.; Tuomainen, T.P. Kauhanen, J.; Nyyssonen, K.; Lakka, H.M.; Uusitupa, M.I.; Salonen, J.T. Leucine7 to proline7 polymorphism in the preproneuropeptide Y is associated with the progression of carotid atherosclerosis, blood pressure and serum lipids in Finnish men. Atherosclerosis 2001, 159, 145-151.
153. Erkkila, A.T.; Lindi, V.; Lehto, S.; Laakso, M.; Uusitupa, M.I. Association of leucine 7 to proline 7 polymorphism in the preproneuropeptide Y with serum lipids in patients with coronary heart disease. Mol. Genet. Metab. 2002, 75, 260-264.
154. Jarvisalo, M.J.; Jartti, L.; Karvonen, M.K.; Pesonen, U.; Koulu, M.; Marniemi, J.; Hammar, N.; Kaprio, J.; Paakkunainen, U.; Simell, O.; Raitakari, O.T.; Ronnemaa, T. Enhanced endothehum-dependent vasodilation in subjects with Proline7 substitution in the signal peptide of neuropeptide Y. Atherosclerosis 2003, 167, 319-326.
155. Wallerstedt, S.M.; Skrtic, S.; Eriksson, A.L.; Ohlsson, C.; Hedner, T. Association analysis of the polymorphism T1128C in the signal peptide of neuropeptide Y in a Swedish hypertensive population. J. Hypertens. 2004, 22, 1277-1281.
156. Ding, B.; Kull, B.; Liu, Z.; Mottagui-Tabar, S.; Thonberg, H.; Gu, H.F.; Brookes, A.J.; Grundemar, L.; Karlsson, C.; Hamsten, A.; Amer, P.; Ostenson, C.G.; Efendic, S.; Monne, M.; von Heijne, G.; Eriksson, P.; Wahlestedt, C. Human neuropeptide Y signal peptide gain-of-function polymorphism is associated with increased body mass index: possible mode of function. Regul. Pept. 2005, 127, 45-53.
157. Tomaszewski, M.; Charchar, F.J.; Lacka, B.; Pesonen, U.; Wang, W.Y.; Zukowska-Szczechowska, E.; Grzeszczak, W.; Dominiczak, A.F. Epistatic interaction between beta2-adrenergic receptor and neuropeptide Y genes influences LDL-cholesterol in hypertension. Hypertension 2004, 44, 689-694.
158. Ogawa, T.; Kitamura, K.; Kangawa, K.; Matsuo, H.; Eto, T. Platelet neuropeptide Y in spontaneously hypertensive rats. J. Hypertens. 1992, 10, 765-771.
159. Zukowska-Grojec, Z.; Golczynska, M.; Shen, G.H.; Torres-Duarte, A.; Haass, M.; Wahlestedt, C.; Myers, A.K. Modulation of vascular function by neuropeptide Y during development of hypertension in spontaneously hypertensive rats. Pediatr. Nephrol. 1993, 7, 845-852.
160. Bohm, M.; Grabel, C.; Knorr, A.; Erdmann, E. Treatment in hypertensive cardiac hypertrophy, I. Neuropeptide Y and beta-adrenoceptors. Hypertension 1995, 25, 954-961.
161. Abdel-Samad, D.; Jacques D.; Perreault, C.; Provost C. NPY regulates human endocardial endothelial cell function. Peptides 2007, 28, 281-287.